Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.
about
Sulphonylurea monotherapy for patients with type 2 diabetes mellitusSulphonylurea monotherapy for patients with type 2 diabetes mellitusEarly Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular TrialsClinical Implications of Glucose Variability: Chronic Complications of DiabetesMonounsaturated fatty acids, olive oil and health status: a systematic review and meta-analysis of cohort studies.Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitusSummation of blood glucose and TAG to characterise the 'metabolic load index'.Metrics for glycaemic control - from HbA1c to continuous glucose monitoring.Differences between healthy adults and patients with type 2 diabetes mellitus in reactivity of toe microcirculation by ultrasound combined with a warm bath testDiabetes technology: markers, monitoring, assessment, and control of blood glucose fluctuations in diabetes.Pramlintide reduces the risks associated with glucose variability in type 1 diabetes.Reduced daily risk of glycemic variability: comparison of exenatide with insulin glargine.The median is not the only message: a clinician's perspective on mathematical analysis of glycemic variability and modeling in diabetes mellitus.Do data in the literature indicate that glycaemic variability is a clinical problem? Glycaemic variability and vascular complications of diabetes.Diabetes: glycaemic control in type 2.Optimizing display, analysis, interpretation and utility of self-monitoring of blood glucose (SMBG) data for management of patients with diabetes.Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? YesCarotid ultrasonography: A potent tool for better clinical practice in diagnosis of atherosclerosis in diabetic patients.Late cardiovascular consequences of gestational diabetes mellitus.Intensive glucose lowering and cardiovascular disease prevention in diabetes: reconciling the recent clinical trial data.Effect of acarbose to delay progression of carotid intima-media thickness in early diabetes.The incretin system and cardiometabolic diseasePramlintide and the treatment of diabetes: a review of the data since its introduction.A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin.Is A1C Variability an Independent Predictor for the Progression of Atherosclerosis in Type 2 Diabetic Patients?A single-center, open, comparative study of the effect of using self-monitoring of blood glucose to guide therapy on preclinical atherosclerotic markers in type 2 diabetic subjectsThe tsim tsoum approaches for prevention of cardiovascular diseaseBreaking up prolonged sitting reduces postprandial glucose and insulin responses.Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factorsHbA₁(c) and mean blood glucose show stronger associations with cardiovascular disease risk factors than do postprandial glycaemia or glucose variability in persons with diabetes: the A1C-Derived Average Glucose (ADAG) study.Efficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide.Glycemic variability and oxidative stress: a link between diabetes and cardiovascular disease?A randomized crossover study to assess the effect of an oat-rich diet on glycaemic control, plasma lipids and postprandial glycaemia, inflammation and oxidative stress in Type 2 diabetes.Strain-blood pressure index for evaluation of early changes in elasticity of anterior tibial artery in patients with type 2 diabetes mellitusCarotid intima-media thickness as a surrogate marker of cardiovascular disease in diabetes1,5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions.Diabetes: glycaemic control in type 2 (drug treatments).A randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of Candesartan on the insulin sensitivity on non diabetic, non hypertense subjects with dysglyce mia and abdominal obesity. "ARAMIA"Glucose and triglyceride excursions following a standardized meal in individuals with diabetes: ELSA-Brasil study.Cardiovascular disease in diabetes: where does glucose fit in?
P2860
Q24186660-15D024C4-171F-42BC-B979-078418FD379DQ24197884-7D6A1D1D-ED2A-472F-8624-BC15D107DCD8Q26767164-0334E1F4-6ED2-4342-B064-A6B6476B08FEQ26801671-6A3D0FFE-0918-4247-AED5-23E9F0C7BEE7Q27692053-F2EC7C06-1736-4D48-8D87-4060225E78CCQ28219328-B7440690-C67D-43A3-96CB-701FB3323B85Q30244149-034F3D9C-D3DA-47F6-9D33-B4287EC6BC37Q30252932-01A308D1-701E-4876-8902-1D4C53B3001BQ30354434-6090F12C-DDDB-4918-BF3C-98613D93C861Q30416241-6184132C-76EC-42DE-93FE-3232F3B9E518Q30434101-140E15E0-B93D-4132-A319-009272C30917Q30438126-EB6C91E5-91F6-4E94-B03B-DB91871515E0Q30438605-DC123AA2-0641-4473-8E8C-A04A654C8260Q30666747-09AC8894-7173-470C-A66C-DB65DE3C16D0Q33446693-26E12173-66C4-4C3C-A8C3-30A9B7B4EF45Q33514840-83F736DC-FC05-47F4-8F81-F975213869CCQ33610682-DCB60D69-DE28-4068-B29B-2E7D0AE72514Q33628605-0DDB4D7A-48B7-4E04-8092-F1BE120AE695Q33687575-393B3C36-4373-4417-9C96-B1E9D3FFDDE0Q33753663-35DC0044-D622-416D-8D9A-D3E285469F37Q33773432-E764540D-5345-4801-AF85-BD44686F5B78Q33776092-AA84D511-1BFA-4694-97B6-A12CE5B3CE32Q33896433-1099F2D1-2B59-4620-9B87-35D4570E959FQ33913060-F12C997D-F7EC-40F3-B955-FE15D43EEEFDQ33969587-F3E5A4C9-985D-4603-9944-9C73ECD841D5Q34018145-0D8BB532-5F83-42D0-962D-FE4979BC32CDQ34021697-9EA012C2-D673-4A72-BC5E-12CC1DB1451FQ34030881-72C4014F-EF25-4B75-9C8A-4F666B2E98C3Q34133889-E71454B7-BAB4-4D34-8FC8-EB1B51367466Q34372793-31E8269E-369C-49A2-8A0C-06D6FA4691F5Q34407865-0A07AF80-C76B-48B6-B1A3-88BE5C073DB8Q34486820-3FF29044-5B20-4628-891C-52572B424055Q34511538-0FD4DFAE-DFBB-4CA0-8A9F-E8E2A8509171Q34609522-FB55C8B7-F3DE-49EC-8F8C-A5722C4379F4Q34721194-120163F5-C5CC-4DCD-87DF-8DAC6042E0ADQ34726941-9EABDFA9-1091-4068-814E-0F5621801DEDQ34829290-8400E6C5-3FF6-47EF-8F20-19A813A8A4D6Q35072984-44DEF912-55CE-412A-A16E-D60EC6619C55Q35085599-ECA193F5-81E3-4C83-947F-24836CE87A9BQ35137148-66ACD3A6-100C-4389-809D-2785C493796B
P2860
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Regression of carotid atherosc ...... a in type 2 diabetes mellitus.
@en
Regression of carotid atherosc ...... a in type 2 diabetes mellitus.
@nl
type
label
Regression of carotid atherosc ...... a in type 2 diabetes mellitus.
@en
Regression of carotid atherosc ...... a in type 2 diabetes mellitus.
@nl
prefLabel
Regression of carotid atherosc ...... a in type 2 diabetes mellitus.
@en
Regression of carotid atherosc ...... a in type 2 diabetes mellitus.
@nl
P2093
P921
P1433
P1476
Regression of carotid atherosc ...... ia in type 2 diabetes mellitus
@en
P2093
Campanian Postprandial Hyperglycemia Study Group
Francesco Nappo
Katherine Esposito
Raffaele Marfella
P304
P356
10.1161/01.CIR.0000134501.57864.66
P407
P577
2004-06-14T00:00:00Z